Anavex Advances Second Lead Compound; Initiates Scale-Up Manufacturing of ANAVEX 1-41

ANAVEX 2-73 Advances Phase I Clinical Trial for Alzheimer’s Disease

Anavex Comments on New Alzheimer’s Disease Diagnostic Guidelines

Anavex Appoints Robert Chisholm to Board of Directors

Anavex First-in-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease

Anavex Appoints Dr. Christopher Shackleton as an Advisor

Anavex to Hold Annual Meeting on April 11, 2011

Anavex Screening Healthy Volunteers for Phase I, First-in-Human Clinical Study in Alzheimer’s disease

Anavex Management to Hold Live Investor Conference Call Today at 4:30PM ET